by healthadvances Posted on February 22, 2023 The Humira Biosimilars Have Arrived! Will They Make a Difference? Read More
by healthadvances Posted on January 4, 2023 Maturation of Modalities and Targeting Strategies in Oncology: A Review of Recent and Upcoming Approvals Read More
by healthadvances Posted on July 21, 2022 Digital Biomarkers – The Future of Precision Medicine Read More
by healthadvances Posted on June 24, 2022June 24, 2022 From Treating Cancer to Curing Cancer – The Promise of mRNA Vaccines in Oncology Read More
by healthadvances Posted on June 16, 2022June 16, 2022 ASCO 2022: Striving to Ensure No Patient is Left Behind Read More
by healthadvances Posted on July 30, 2020January 13, 2021 Value Creation in Molecular Diagnostics: A Game of Luck or Skill? Read More
by healthadvances Posted on March 30, 2020April 13, 2020 Key Trends and Developments in the Chinese Oncology Market Read More
by healthadvances Posted on June 7, 2019April 13, 2020 Highlights from Health Advances Executive Panel – Precision Medicine: Oncology and Beyond Read More
by healthadvances Posted on April 16, 2019April 13, 2020 Better Market Access in China – Government Improves Pricing and Reimbursement Environment Read More
by healthadvances Posted on April 7, 2019April 13, 2020 Keytruda, a case study for the improved regulatory environment in China Read More
by healthadvances Posted on December 19, 2018April 13, 2020 The Year That Was: Oncology Edition Read More
by healthadvances Posted on March 14, 2018April 15, 2020 Seattle’s Journey to the Summit of Cancer Commercialization Read More
by healthadvances Posted on July 14, 2015April 15, 2020 CAR-T: The Emperor’s New Clothes or The Second Coming? Read More
by healthadvances Posted on July 2, 2015April 15, 2020 Juno Therapeutics and Celgene Ink 10 Year Deal Read More
